Pharmaceutical cGMPs For The 21st Century — A Risk-Based Approach

In August 2002, the Food and Drug Administration announced a significant new initiative to enhance and modernize the regulation of pharmaceutical manufacturing and product quality. The initiative, which this final report describes in detail, was intended to modernize FDA's regulation of pharmaceutical quality for veterinary and human drugs and select human biological products such as vaccines. Submitted by the Food and Drug Administration (FDA)